History -- Part 3

• 5/26/16: Enrolled on clinical trial with a pan-fibroblast growth factor receptor (FGFR) inhibitor.
• 6/1/16: Dramatic clinical improvement observed.
• Continued on clinical trial until progression, November 2016.
• Due to clinical deterioration, this patient elected to forgo additional therapy and to enroll in hospice.